In the European Union,<unk>  is contraindicated in people with active, severe infections. While this is not listed as a contraindication under the US FDA approval, there is a boxed warning that recommends testing for hidden tuberculosis infection before treatment and monitoring for signs of an infection during therapy with<unk> .
Sarilumab
Emapalumab
Burosumab
Olaratumab
Dupilumab
Evolocumab
Anifrolumab
Alirocumab